Compare Neurocrine Biosciences Inc (NBIX) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Impinj Inc — how do they compare? Neurocrine Biosciences Inc trades at $140.75 (market cap $14.36B), while Impinj Inc trades at $186.31 (market cap $5.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.6× Impinj Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Impinj Inc for 22 Days on average.
| NBIX | PI | |
|---|---|---|
Market Cap | $14.36B | $5.60B |
Volume | 1,237,180 | 9,929 |
Sector | Health | Technology |
52-Week High | $185.50 | $241.91 |
52-Week Low | $123.10 | $91.34 |
Typical Hold Time | 23 Days | 22 Days |
Enterprise Value | $14.37B | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Impinj (PI) trades at $186.53, down 2.36% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 16 buy ratings and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations with $0.86 EPS, while revenue growth continues but net margins remain negative at -7.26%. The company maintains solid cash flow from operations of $58.75M in 2025.
Investment outlook balances growth potential against profitability challenges. The RAIN RFID technology market offers expansion opportunities, but elevated valuations (P/S 14.83) and negative ROE (-12.87%) present risks. Near-term catalysts include Q3 2026 results, while competitive pressures and execution risks require monitoring for sustained shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
